Table 2 The details and characteristics of the 16 included studies divided into severe and non-severe groups
From: What can the neurological manifestations of COVID-19 tell us: a meta-analysis
Study | Severe | Non-severe | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Case | Headache | Dizziness | Seizure | Myalgia | Smell impairment | Taste dysfunction | Case | Headache | Dizziness | Seizure | Myalgia | Smell impairment | Taste dysfunction | |
Ling Mao et al. [8] | 88 | 15 | 17 | 1 | / | 3 | 3 | 126 | 13 | 19 | / | / | 8 | 9 |
Antoine Guilmot et al. [42] | 9 | / | / | 1 | / | / | / | 6 | / | / | 1 | / | 2 | / |
Nitesh Gupta et al. [68] | 32 | 13 | / | / | / | / | / | 168 | 9 | / | / | / | / | / |
François Lersy et al. [84] | 47 | 1 | / | 3 | / | / | / | 11 | 2 | / | 3 | / | / | / |
Rajesh Benny et al. [85] | 47 | 8 | / | 9 | / | 7 | 2 | 53 | 13 | / | 9 | / | 3 | 6 |
Daniel Schonfeld et al. [94] | 5652 | 1168 | / | 60 | 1002 | 380 | 320 | 41,703 | 12,517 | / | 223 | 9572 | 5893 | 4508 |
Caizheng Yu et al. [110] | 864 | / | / | / | 31 | / | / | 799 | / | / | / | 26 | / | / |
Shenae Samuels et al. [111] | 147 | 21 | / | / | 30 | / | / | 346 | 26 | / | 3 | 86 | / | / |
Eric M. Liotta et al. [113] | 134 | 43 | 40 | / | 56 | 11 | 17 | 375 | 149 | 111 | 4 | 172 | 47 | 64 |
Carlos Manuel Romero-Sánchez et al. [129] | 329 | 38 | 17 | 4 | 44 | 9 | 13 | 512 | 81 | 34 | 2 | 101 | 32 | 39 |
Xudong He et al. [132] | 23 | 3 | 4 | / | 8 | / | / | 54 | 1 | 5 | / | 10 | / | / |
Mehran Ghaffari et al. [138] | 233 | 60 | 22 | 7 | 101 | 42 | 41 | 128 | 49 | 12 | 3 | 73 | 27 | 28 |
Man Amanat et al. [140] | 299 | 24 | 29 | / | 75 | / | / | 574 | 86 | 75 | / | 142 | / | / |
Egehan Salepci et al. [169] | 45 | 11 | 4 | / | / | 6 | 12 | 178 | 48 | 1 | / | / | 65 | 65 |
J. Zhang et al. [170] | 409 | 13 | 21 | / | 30 | / | / | 254 | 7 | 2 | / | 33 | / | / |
Altunisik E et al.(180) | 11 | 4 | 2 | / | / | / | / | 40 | 5 | 5 | / | / | 3 | 3 |